AZ-BMS diabetes combo recommended for EU, but will corporate combo survive?
This article was originally published in Scrip
Executive Summary
The recommended approval in Europe of a metformin/dapagliflozin drug combination by the CHMP on 21 November may yet prove to be an allegory for the way in which the business relationship between the drug's sponsors, AstraZeneca and Bristol-Myers Squibb, plays out over the coming months. The anticipated approval that would follow the recommendation could tip the balance of power in the relationship between the two companies in favour of AstraZeneca.